AUTHORS
Muhammad Samsoor Zarak, MD, Neha Agarwal2, Bita Sahaf, PhD3, Mark P Hamilton, MD4, Melody Smith, MD,MS5, Sushma Bharadwaj, MD6, Wen-Kai Weng, MD, PhD7, Neel Gupta, MD8, Saurabh Dahiya, MD, FACP9, David Miklos, MD, PhD10, Mathew J. Frank, MD, PhD11
AFFILIATIONS
1 Stanford University, Stanford, United States
2 Stanford University, Stanford, United States
3 Stanford University, Stanford, United States
4 MD Anderson Cancer Center, Houston, Texas, United States
5 Stanford University, Stanford, United States
6 Stanford University, Stanford, United States
7 Stanford University, Stanford, United States
8 Stanford University, Stanford, United States
9 Stanford University, Stanford, United States
10 Stanford University, Stanford, United States
11 Stanford University, Stanford, United States
ABSTRACT
Introduction:
Secondary central nervous system large B-cell lymphoma (sCNSL) is a rare and aggressive disease associated with poor outcomes. Although CD19-targeted CAR-T therapy (CAR19) has shown substantial efficacy in systemic DLBCL, patients with active CNS LBCL were excluded from pivotal trials because of concerns regarding neurotoxicity. Despite the expanding use of CAR-T therapy in CNS disease, evidence regarding its efficacy, safety, and mechanisms of resistance remains limited. We conducted a retrospective observational study of patients with active sCNSL treated with CAR-T therapy to evaluate clinical outcomes and factors associated with response and resistance.
Methods:
This single-center study included 30 patients with active sCNSL treated with CAR-T therapy at Stanford University from October 2017 to June 2025. Primary outcomes were progression-free survival (PFS) and overall survival (OS). Secondary and exploratory outcomes included overall response, safety, clinicopathologic predictors, and mechanisms of CAR-T resistance. Toxicities were graded according to ASTCT criteria. Survival outcomes were estimated via Kaplan–Meier analysis and compared using log-rank testing; continuous variables were compared via Mann–Whitney U testing; p-values <0.05 were considered significant. Quantification of CD4+, CD8+, and total CAR+ T cells on Days 7, 14, 21, and 28 was performed as described (Hamilton Blood Adv 2024).
Results:
The median age was 63.5 years, 66.7% were male, and histologic subtypes included DLBCL (70%), high-grade B-cell lymphoma (23%), and transformed follicular lymphoma (7%). 43% and 47% of tumors were germinal center B-cell (GCB) and non-GCB phenotype, respectively (with 10% unknown). Concurrent CNS and systemic disease occurred in 80%, with parenchymal involvement in 46.7%. 29 patients received axi-cel and 1 received liso-cel. 20 (66.7%) patients had 3+ prior lines of therapy.
After a median follow-up of 38.4 months, CRS occurred in 93.3% (grade (gr) 3–4, 3.3%), ICANS in 73.3% (gr 3–4, 26.7%), and 2 cases (6.7%) of IEC-HS (both gr3). 1 patient died before initial post-treatment evaluation from gram-negative rod sepsis (the only case of non-relapse mortality), and 25 of 29 (86%) evaluable patients had a response. The median PFS and OS were 6.25 months (95% CI, 2.4– NR) and 26.4 months (95% CI, 4.6–NR), respectively. The 2-year estimated PFS and OS were 39% and 52%, respectively. Lower pre-lymphodepletion ferritin (below 650 ng/mL) compared to above was associated with superior PFS and OS (P=0.01 and P=0.002, respectively). Those with parenchymal CNS involvement were associated with superior PFS and OS compared with non-parenchymal involvement (P=0.04 and P=0.02, respectively).
18 patients ultimately progressed, and 14 patients had post-relapse samples available for analysis. 4 patients had either no (n=2) or very low CD19 expression (<30% of cells had CD19 expression) (n=2) at the time of relapse. One additional patient was CD19 negative by IHC before CAR-T infusion. Notably, 9 of 13 (69%) and 9 of 11 (82%) available post-treatment tumor samples expressed CD20 and CD22, respectively. Median survival after CAR-T progression was 2.1 months (95% CI, 1.0–7.6) with only 3 of 18 patients surviving 12 months. Of these 3 patients, one received a CD22-directed CAR T-cell therapy, and two received a CD20 x CD3 bispecific antibody. Additionally, in total, 5 patients received a bispecific antibody after CAR19 progression, and 3 achieved a response.
When evaluating CAR T-cell expansion, the 26 patients with sCNSL with available data exhibited similar CD4+, CD8+, and total CAR T cell expansion as compared to a previously reported cohort of 179 patients without sCNSL (Hamilton Blood Adv 2024). Among patients with sCNSL, those achieving a complete response (n=12) versus progressive disease (n=14) trended toward higher CD4+, CD8+, and total CAR T-cells on Day 14, 21, and 28, but did not reach statistical significance.
Conclusions:
CAR19 provided durable clinical benefit to a clinically significant number of patients with sCNSL. Rates of overall and severe CRS and ICANS were similar to those of patients with LBCL without CNS involvement. Approximately one-third of patients with sCNL experience CD19 loss or downregulation at the time of relapse, similar to those patients without sCNSL. Patients relapsing after CAR19 had dismal outcomes (median OS of 2.1 months), highlighting a significant unmet clinical need.
DISCLOSURES
Muhammad Samsoor Zarak, MD: No relevant conflicts of interest to declare.